Abstract Purpose: Malignant tumors are capable of degrading the surrounding extracellular matrix, resulting in local invasion or metastasis. Urokinase-type plasminogen activator (uPA) and its cell surface receptor (uPAR) are central molecules in one of the major protease systems involved in extracellular matrix degradation. Noninvasive imaging of this receptor in vivo with radiolabeled peptides that specifically target uPAR may therefore be useful to decipher the potential invasiveness of malignant lesions. Experimental Design: In this study, we developed a 64 Cu-labeled uPAR-binding peptide for positron emission tomography (PET) imaging. A linear, high-affinity uPAR-binding peptide antagonist AE105 was conjugated with 1,4,7,10-tetraazadodecane-N,N ¶,N 00 ,NØ-tetraacetic acid (DOTA) and labeled with 64 Cu for microPET imaging of mice bearing U87MG human glioblastoma (uPAR positive) and MDA-MB-435 human breast cancer (uPAR negative). Results: Surface plasmon resonance measurements show that AE105 with DOTA conjugated at the a-amino group (DOTA-AE105) has high affinity toward uPAR. microPET imaging reveals a rapid and high accumulation of Cu-DOTA-AE105 is specifically inhibited by a nonlabeled antagonist. Conclusion: The successful demonstration of the ability of a 64 Cu labeled uPAR-specific probe to visualize uPAR expression in vivo may allow clinical translation of this class of radiopharmaceuticals for uPAR-positive cancer detection and patient stratification for uPA/uPAR systembased cancer therapy.
,NØ-tetraacetic acid (DOTA) and labeled with 64 Cu for microPET imaging of mice bearing U87MG human glioblastoma (uPAR positive) and MDA-MB-435 human breast cancer (uPAR negative). Results: Surface plasmon resonance measurements show that AE105 with DOTA conjugated at the a-amino group (DOTA-AE105) has high affinity toward uPAR. microPET imaging reveals a rapid and high accumulation of 64 Cu-DOTA-AE105 in uPAR-positive U87MG tumors (10.8 F 1.5 %ID/g at 4.5 hours, n = 3) but not in uPAR-negative MDA-MB-435 tumors (1.2 F 0.6%ID/g at 4.5 hours, n = 3). Specificity of this peptide-based imaging of uPAR was validated by further control experiments. First, a nonbinding variant of AE105 carrying a single amino acid replacement (Trp!Glu) does not target U87MG tumors in vivo. Second, targeting of U87MG tumors by 64 Cu-DOTA-AE105 is specifically inhibited by a nonlabeled antagonist. Conclusion: The successful demonstration of the ability of a 64 Cu labeled uPAR-specific probe to visualize uPAR expression in vivo may allow clinical translation of this class of radiopharmaceuticals for uPAR-positive cancer detection and patient stratification for uPA/uPAR systembased cancer therapy.
Malignant tumors are capable of degrading the surrounding extracellular matrix, resulting in local invasion or metastasis. Urokinase-type plasminogen activator (uPA) and its cell surface receptor (uPAR) are central molecules for cell surfaceassociated plasminogen activation both in vitro and in vivo (1, 2) . High expression of uPA and uPAR in many types of human cancers correlate with malignant tumor growth and associate with a poor prognosis, possibly indicating a causal role for the uPA/uPAR system in cancer progression and metastasis (3) . Studies by immunohistochemistry and in situ hybridization indicate that expression levels of the components from the uPA system are generally very low in normal tissues and benign lesions (4 -8) . It has also been reported that the uPA/uPAR system is involved in regulating cell-extracellular matrix interactions by acting as an adhesion receptor for vitronectin and by modulating integrin function (9) . Based on these properties, the uPA/uPAR system is consequently considered an attractive target for cancer therapy (1) .
To meet the demand for a rapid development and potential clinical application of anticancer therapy based on uPA/uPAR system, it is desirable to develop noninvasive imaging methods to visualize and quantify uPA and/or uPAR expression in vivo.
Using an activatable fluorescent probe approach, optical imaging of tumor-associated uPA activity has been accomplished (10 -12) . In the present study, we explored the possibility for specific in vivo imaging of uPAR in xenotransplanted tumor models in mice using a small linear peptide with high affinity for human uPAR (13) 
Materials and Methods
All commercially available chemical reagents were used without further purification. 1,4,7,10-Tetraazadodecane-N,N ¶,N 00 ,NØ-tetraacetic acid (DOTA) was purchased from Macrocyclics. 1-Ethyl-3-[3-(dimethylamino)-propyl] carbodiimide, N-hydroxysulfonosuccinimide, and Chelex 100 resin (50-100 mesh) were purchased from Aldrich. The peptide antagonist AE105 (D-Cha-F-s-r-Y-L-W-S) and a nonbinding variant of AE105 (AE105 mut , D-Cha-F-s-r-Y-L-E-S) were synthesized by Peptides International. Human recombinant uPAR (residues 1-283) was produced by Drosophila melanogaster S2 cells (15) after deletion of the COOH-terminal signal sequence (residues 284-313) responsible for its membrane attachment by a glycolipid anchor (16) , and the secreted protein was purified from the supernatant by a one-step affinity chromatography using an immobilized peptide antagonist (17) . Activesite mutated, human pro-uPA S356A was produced recombinantly by S2 cells and affinity purified using a monoclonal anti-uPA antibody (18) . 64 Cu was obtained from University of Wisconsin-Madison. Analytical and semipreparative reverse-phase high-performance liquid chromatography (HPLC) was done based on the reference conditions (19) .
DOTA conjugation and radiolabeling. DOTA was activated and conjugated to AE105 and AE105 mut according to the reference procedure (19) . AE105 or AE105 mut was dissolved in DMSO and 5 Eq DOTA-OSSu activated ester was added. The reaction mixture in buffer/DMSO was adjusted to pH 8.5 with 0.1 N NaOH and was allowed to incubate at 4jC for overnight. The DOTA-AE105 conjugate was purified by semipreparative HPLC and obtained as white powder in 52% yield (analytical HPLC retention time R t , 19.1 min). Matrixassisted laser desorption/ionization time-of-flight mass spectrometry: m/z 1,612. Cu labeling procedure were provided in an earlier report (19) . In brief, 20 AL 64 CuCl 2 (74 MBq in 0.1 N HCl) was diluted in 400 AL of 0.1 N sodium acetate (pH 6.5) and added to 20 Ag DOTA conjugate. The reaction mixture was incubated for 1 h at 50jC. 64 Culabeled peptide was subsequently purified by analytical HPLC and the radioactive peak containing the desired product was collected. After removal of the solvent by rotary evaporation, the conjugated peptide tracer was reconstituted in 800 AL PBS and passed through a 0.22 Am syringe filter for in vivo animal experiments.
Binding of peptide antagonists to human uPAR as measured by surface plasmon resonance. To evaluate the effect of DOTA modification on the affinity for uPAR, the binding kinetics of AE105 and DOTA-AE105 to immobilized uPAR were measured in real time by surface plasmon resonance employing a Biacore3000 (Biacore International). Purified recombinant uPAR (residues 1-283) was therefore immobilized on a CM5-sensor chip by amine coupling using N-hydroxysulfonosuccinimide/1-ethyl-3-[3-(dimethylamino)-propyl] carbodiimide. In brief, 30 AL of three different concentrations of uPAR (2-10 Ag/mL) in 10 mmol/L sodium acetate (pH 5.0) were injected at a flow rate of 5 AL/min, providing coupling yields of 1,200 to 2,700 RU. For the evaluation of binding kinetics, serial 2-fold dilutions of the synthetic peptides in running buffer [10 mmol/L HEPES, 150 mmol/L NaCl, 3 mmol/L EDTA, and 0.005% (v/v) surfactant P20 (pH 7.4)] covering 0.5 Amol/L to 4 nmol/L were injected at a flow rate of 50 AL/min for 300 s at 20jC. Peptide-uPAR complex dissociation was subsequently recorded for 750 s followed by regeneration using two injections of 10 AL of 0.1 N acetic acid containing 0.5 N NaCl. Data processing and calculation of kinetic rate constants k on and k off by nonlinear regression analysis was done essentially as described (18) .
For competition analysis recombinant, pro-uPA S356A (0.5 and 2 Ag/mL) was immobilized on the CM5-sensor chip by amine chemistry, yielding coupling levels of 642 and 4,600 RU, respectively. Soluble uPAR (10 nmol/L) preincubated for 10 min with serial dilutions of AE105, DOTA-AE105, or DOTA-AE105 mut were allowed to interact with the immobilized pro-uPA for 300 s at 20jC with a flow rate of 50 AL/min running buffer. The concentrations of free, unoccupied uPAR in these competition experiments were calculated from the initial association rates (recorded from 260 to 270 s) and compared with the corresponding association rates measured for calibration experiments using serial dilutions of uPAR without any competitor (standard curve is linear from 0.2 to 20 nmol/L soluble uPAR; Fig. 2B, right) .
Cell lines and animal models. MDA-MB-435 human breast cancer and U87MG human glioblastoma cell lines were purchased from the American Type Culture Collection and grown in Leibovitz L15 and MEM supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/mL penicillin, and 100 Ag/mL streptomycin (Invitrogen) at 37jC in a humidified atmosphere without and with 5% CO 2 , respectively. All animal experiments were done in compliance with the Guidelines for the Care and Use of Research Animals established by the Stanford University Animal Studies Committee. Female athymic nude mice (nu/nu) were obtained from Harlan at age 4 to 6 weeks and kept under sterile conditions. The tumor cells were harvested and suspended in sterile PBS at a concentration of 5 Â 10 7 viable cells/mL. Viable U87MG cells in sterile PBS (100 AL) were injected in the front leg of female nude mice and MDA-MB-435 cells were inoculated under the mammary fat pad. The tumors were allowed to grow 3 to 4 weeks until 200 to 500 mm 3 in volume. Tumor growth was followed by caliper measurements of the perpendicular dimensions.
Reverse transcription-PCR. The expression of uPA, uPAR, PAI-1, and PAI-2 mRNA was determined by reverse transcription-PCR with GoTaq Green Master Mix (Promega). Total RNA was isolated from different cancer cells with RNeasy kit (Qiagen) and the total RNA concentration in each sample was measured by absorbance at 260 nm. PCR conditions were 94jC for 2 min (1 cycle) and 30 cycles at 94jC for 30 s, 58jC for 30 s, and 72jC for 30 s and a final incubation at 72jC for 10 min. Human h-actin was used as an internal standard. The PCR products were loaded for 1% agarose gel electrophoresis.
Flow cytometry for uPAR expression. Cells were collected and washed by PBS and then kept in PBS supplemented with 1% bovine serum albumin and 0.03% sodium azide. Cells were then incubated with a mouse anti-human uPAR monoclonal antibody 3936 (American Diagnostica) at 4jC for 30 min. After washing with PBS in the presence of 1% bovine serum albumin, the cells were incubated with FITCconjugated donkey anti-mouse IgG (DAKO) at 4jC for 30 min. After washing, cells were resuspended in PBS and analyzed using a FACSCalibur (Becton Dickson) with FlowJo analysis software (Tree Star). Mouse IgG isotype was used as negative control.
Western blot for uPAR protein level detection. Cells were harvested and washed three times with PBS and resuspended in 50 AL lysis buffer (Sigma). After centrifugation, the supernatant was collected and the protein concentration was determined by using Bio-Rad protein assay kit (Bio-Rad). Electrophoresis was done on 10% SDS-PAGE with a loading of 60 Ag protein in each lane. Following electrophoresis, the proteins were transferred to a nitrocellulose membrane (Invitrogen). The membrane was then blocked with 5% (w/v) nonfat dry milk in 0.1% (v/v) Tween 20-TBS for 1 h at room temperature. Primary mouse antibody against human uPAR (1:100 dilution; American Diagnostica) was added into the buffer for further incubation of 2 h. The membrane was washed with 0.1% (v/v) Tween 20-TBS three times and allowed to incubate in 0.1% (v/v) Tween 20-TBS buffer containing horseradish peroxidase -conjugated donkey anti-mouse IgG (1:1,000 dilution; ImmunoPure, Pierce) for 1 h at room temperature. After washing, the uPAR was detected with ECL Western Blotting Detection Reagents (GE Healthcare) and the image was developed on a Kodak BioMax Light Film (Kodak).
microPET studies. Positron emission tomography (PET) imaging of tumor-bearing mice was done on a microPET R4 rodent model scanner (Concorde Microsystems) as described earlier (19 Cu-DOTA-AE105 mut via the tail vein. Static scans (5 or 10 min) were acquired at 1, 4.5, and 22 h postinjection. The images were reconstructed by a twodimensional ordered-subsets expectation maximum algorithm and no correction was applied for attenuation and scatter. For each microPET scan, three-dimensional regions of interest were drawn over the tumor, liver, kidneys, and muscle on decay-corrected whole-body coronal images. The average radioactivity concentration within a tumor or an organ was obtained from mean pixel values within the regionof-interest volume, which were converted to counts/mL/min by using a conversion factor. Assuming a tissue density of 1 g/mL, the counts/ mL/min were converted to counts/g/min and then divided by the injected dose to obtain an imaging region of interest -derived %ID/g tissue. For a receptor-blocking experiment, mice bearing U87MG tumors were preloaded with 15 mg/kg AE105 for 30 min (i.v. injection) followed by injection of 9.3 MBq 64 Cu-DOTA-AE105 (f0.1 mg/kg). The mice were then scanned (5-min static) 4.5 h later.
Immunohistologic staining of tumor tissues. Tumor samples were gathered after sacrificing the animals and the tumors were sectioned with a cryostat microtome. Tissue sections were equilibrated at room temperature for 25 min and fixed with ice-cold acetone for 10 min.
After drying at room temperature, these sections were blocked with 5% milk in PBS for 1 h before incubation with the anti-uPAR antibody for 1.5 h at room temperature (diluted 1:200 in PBS/1% milk/0.2% Tween 20; American Diagnostica). Excess antibody was removed by washing the tissue sections with TBS (pH 7.2) containing 0.2% Tween 20 before the secondary antibody rabbit anti-human polyclonal IgG was added (diluted 1:100 in PBS/1% milk/0.2% Tween 20; American Diagnostica) and incubated for 1 h in dark room at room temperature. Excess antibody was removed by washing with TBS-Tween 20 and rinsing with PBS and the immunoreactivity was visualized by the fluorescence from Cy3. The coverslips were then mounted on the slides with Vectashield Mounting Medium with 4 ¶,6-diamidino-2-phenylindole (Vector Lab) and the tissue sections were examined under the microscope (Carl Zeiss Axiovert 200M; Carl Zeiss).
Statistical analysis. Quantitative data were expressed as mean F SD. Means were compared using one-way ANOVA and Student's t test. P values < 0.05 were considered statistically significant.
Results
Chemistry and radiochemistry. In aqueous solution, DOTA was activated with 1-ethyl-3-[3-(dimethylamino)-propyl] carbodiimide/N-hydroxysulfonosuccinimide, and the resulting DOTA-OSSu was conjugated to either AE105 or AE105 mut , providing DOTA-AE105 in 52% yield and DOTA-AE105 mut in (Fig. 1) . By analytical HPLC, we observed no significant difference in retention time between 64 Cu-labeled tracer and the corresponding unlabeled conjugate. 64 Cu labeling was achieved in 80% to 90% decay-corrected yield with radiochemical purity of >98%. The specific activity of 64 Cu-DOTA-AE105 and 64 Cu-DOTA-AE105 mut was estimated to be f23 MBq/nmol (0.62 Ci/Amol). Some concerns related to the stability of 64 Cu-DOTA complex have been raised in the literature (20 -22) . Therefore, the metabolic stability of 64 Cu-DOTA-AE105 was evaluated in U87MG tumor-bearing nude mice using the method described in the literature (19) . The tracer was stable in blood (92% intact tracer), urine (87% intact tracer), and tumor (89% intact tracer) samples at 1 hour after injection. The amount of intact tracer in the kidneys was f61% at 1 hour after injection and this tracer showed rapid metabolism in the liver (32% intact tracer). These data suggest that 64 Cu-DOTA-AE105 is sufficiently stable for in vivo applications.
Affinity and competition measurements for derivatives of AE105 by surface plasmon resonance. To study the effect of DOTA conjugation to the a-amino group of AE105 on the affinity for uPAR, we measured the interactions of AE105 analogues with immobilized uPAR in real-time by surface plasmon resonance and derived the corresponding kinetic rate constants at 20jC. As shown in Table 1 , DOTA conjugation to AE105 resulted in a 3.5-fold increase in the dissociation constant (KD) for the interaction with purified uPAR. The affinity of the AE105-uPAR interaction measured in the present study showed a K D of f15 nmol/L. Under the same conditions, DOTA-AE105 has a K D of 53 nmol/L for the direct interaction with uPAR. We were unable to measure any interaction with the control peptides AE105 mut and DOTA-AE105 mut at concentrations up to 1 Amol/L (data not shown). The huge effect of the Trp!Glu replacement in DOTA-AE105 on uPAR binding was in complete agreement with previous kinetic studies on AE105 with a Trp!Ala replacement (13) . Furthermore, this finding was excellently aligned with the recently solved crystal structure of uPAR in complex with a derivative of AE105 (23) , where the indole side chain of the corresponding Trp was completely buried at the receptor interface where it engaged the deepest region of the hydrophobic cavity (Fig. 2C) . These uPAR-binding properties of the peptides were recapitulated in a solution-phase competition assay, where AE105 and DOTA-AE105 inhibited the interaction between immobilized pro-uPA and uPAR with IC 50 values of 16 and 130 nmol/L, respectively, as measured by surface plasmon resonance (Fig. 2B, left ; Table 1 ). Again, the DOTA-AE105 mut control peptide proved to be highly inefficient exhibiting a >2,300-fold lowered potency compared with DOTA-AE105 in competing the uPAR-pro-uPA interaction ( Fig. 2B ; Table 1 ). These combined results encouraged the following in vivo imaging studies in mice with 64 Cu-DOTA-AE105 as specific probe and DOTA-AE105 mut as an appropriate control peptide for nonspecific effects.
In vitro uPAR expression in U87MG and MDA-MB-435 cells. We selected two human cancer cell lines (U87MG and MDA-MB-435) to evaluate the effect of different levels of uPAR expression. As shown in Fig. 3A , the mRNA levels for the serine protease uPA and its cognate receptor (uPAR) and serpin inhibitor (PAI-1) were all relatively higher in U87MG cells compared with those in MDA-MB-435 cells. PAI-2 expression was not detectable in either cell line. This difference in mRNA level for uPAR was also translated into comparable differences in the protein level as assessed by fluorescence flow cytometry (Fig. 3B ) and Western blot (Fig. 3C) , with U87MG cells expressing uPAR protein more abundantly compared with MDA-MB-435 cells.
microPET imaging of 64 Cu-DOTA-AE105 and 64 Cu-DOTA-AE105 mut in tumor-bearing mice. Mice bearing U87MG tumors (n = 3; uPAR positive) and MDA-MB-435 tumors (n = 3; uPAR negative) were subjected to microPET scans at various time points after i.v. injection of 9.3 MBq 64 Cu-DOTA-AE105. The coronal slices that contain the tumor are shown in Fig. 4 . The uptake of 64 Cu-DOTA-AE105 into U87MG tumors was rapid and high, reaching 7.6 F 0.9, 10.8 F 1.5, and 10.9 F 0.6% ID/g at 1, 4.5, and 22 hours postinjection, respectively. The tumor is clearly visible as early as 1 hour postinjection and the uptake kept increasing and reached a plateau at 4 hours postinjection (Fig. 5) . The accumulation of 64 Cu-DOTA-AE105 in MDA-MB-435 tumor was very low at all time points examined, reaching a level around 1%ID/g, which is only slightly higher than the corresponding levels recorded for muscles. Accordingly, the uptake of 64 Cu-DOTA-AE105 was significantly higher in U87MG tumors compared with those in MDA-MB-435 tumors at all time points examined (P < 0.01; Fig. 5 ).
Due to its lipophilic character, 64 Cu-DOTA-AE105 exhibited a substantial liver uptake at early time points (e.g., 10.9 F 0.6% ID/g at 1 hour postinjection), which dropped steadily over time (e.g. 10.0 F 0.7%ID/g at 4.5 hours and 7.1 F 1.0%ID/g at 22 hours postinjection). Moderate kidney uptake was also observed (e.g., 4.9 F 0.9%ID/g at 1 hour postinjection as NOTE: Purified, recombinant human uPAR (residues 1-283) was immobilized on a Biacore CM5-sensor chip and the interaction with 2-fold serial dilution series of the synthetic peptides in running buffer was measured at 20jC and a flow rate of 50 AL/min. Kinetic rate constants were derived by curve fitting to the recorded sensorgrams using nonlinear regression analysis and K D values were calculated as k off /k on (18) . IC 50 values were derived by solution competition assays using Biacore as described in Materials and Methods.
measured for three U87MG tumor-bearing mice and three MDA-MB-435 tumor-bearing mice). Accumulation of the peptide in most other organs was at a very low level (Fig. 5) .
To confirm the receptor specificity of 64 Cu-DOTA-AE105 in vivo, 64 Cu-labeled AE105 mut (D-Cha-F-s-r-Y-L-E-S) that does not bind to uPAR was also tested. The coronal slices that contain the U87MG tumors are shown in Fig. 4B . The uptake of 64 Cu-DOTA-AE105 mut into U87MG tumors was 1.7 F 0.4, 2.2 F 0.5, and 3.1 F 0.6 %ID/g at 1, 4.5, and 22 hours postinjection, which was significantly lower than the original 64 Cu-DOTA-AE105 (P < 0.005; Fig. 5B ). The receptor specificity of the imaging was further validated by an in vivo competition experiment. The U87MG tumor bearing mice received an i.v. bolus of unlabeled AE105 peptide (15 mg/kg) 30 minutes before the injection of 64 Cu-DOTA-AE105 to saturate unoccupied uPAR. A coronal image obtained 4.5 hours after tracer injection into a U87MG tumor-bearing mouse receiving the bolus of the unlabelled peptide is shown in Fig. 4C . This image was representative for the three mice included in this study. The uptake in the tumor was decreased from 10.8 F 1.5 to 3.7 F 1.3 %ID/g at 4.5 hours by the bolus injection of the unlabeled peptide (P < 0.05; Fig. 5C ).
Immunochemical staining of uPAR expression. After the microPET studies were completed and the majority of the radioactivity had decayed, the mice were sacrificed and frozen tumor sections were stained for human uPAR. Images were taken under the same condition and displayed at the same scale to make sure that the relative brightness observed in the images reflected the difference in uPAR expression level. As can be seen from Fig. 6 , in U87MG tumor sections, the staining signal distributed diffusively among the sections. We did not observe any preferred localization region, whereas, in MDA-MB-435 tumor sections, no apparent staining signals were observed. All in vitro and ex vivo data supported that the high radiotracer accumulation over U87MG tumor region was due to the high expression of uPAR among the tumor, which indicated that 64 Cu-DOTA-AE105 microPET was capable of detecting uPAR expression in a noninvasive mode. 
Discussion
This study shows that 64 Cu-labeled DOTA-AE105 exhibits a specific and high-affinity uPAR binding both in vitro and in vivo. PET imaging of uPAR using 64 Cu-DOTA-AE105 may thus be suitable for real-time and noninvasive monitoring of the location and expression levels of this receptor in vivo during various malignancies.
Accumulating evidence seems to implicate the uPA/uPAR system in cancer invasion (1, 3 -8, 24 -26) and several therapeutic targeting strategies against uPAR have been developed, including antibodies (27, 28) , fusion proteins (29 -31), uPAR-derived therapeutic molecules (32), antisense oligonucleotides (33 -35) , and RNA interference (36 -38) . With a view to therapeutic intervention, it is thus desirable to be able to monitor the continuous change of uPAR status during treatment as well as being able to select those patients that may benefit from such therapy (that is, expressing significant levels of the target protein). To accomplish this, we sought to develop a noninvasive imaging method enabling cancer detection based on uPAR expression.
A high-affinity 9-mer peptide antagonist of the uPA-uPAR interaction (AE105) was developed previously by combinatorial chemistry and surface plasmon resonance by Ploug et al. (13) . The versatility and specificity of this small uPAR-binding peptide is illustrated by the fact that it has been used to establish a specific immunoassay for various uPAR forms in plasma (39) , that it forms the cornerstone in a newly developed one-step affinity purification protocol for human uPAR (17) , that it can target uPAR covalently by photoaffinity labeling (40, 41) , and finally that it was instrumental for solving the first crystal structure of uPAR (23) . In this study, we synthesized a 64 Cu-DOTA-conjugated uPAR-binding peptide AE105 and we have provided direct proof-of-principle evidence for its specific targeting of uPAR-expressing tumors using microPET imaging in vivo.
In U87MG tumor cells, both in vitro analysis (reverse transcription-PCR, Western blot, and fluorescence-activated cell sorting; Fig. 3 ) and ex vivo immunofluorescence staining of xenotransplanted U87MG tumors (Fig. 6 ) reveal that this glioblastoma cell line expresses high levels of uPAR. In contrast, the breast cancer -derived cell line MDA-MB435 has a negligible uPAR expression as confirmed by the same analyses (Figs. 3 and 6 ). These ex vivo findings were nicely recapitulated by in vivo PET imaging as the uptake of 64 Cu-DOTA-AE105 in U87MG tumors increased with time and reached a peak at 22 hours postinjection (10.9 F 0.6%ID/g; Figs. 4 and 5). As predicted, the MDA-MB-435 tumor uptake of 64 Cu-DOTA-AE105 remained close to background levels at all time points. The activity-progress curves suggest that an optimal imaging window may exist as early as 4 hours postinjection.
To further confirm the receptor specificity, we studied the imaging of 64 Cu-DOTA-AE105 mut in U87MG tumor-bearing mice. The aromatic side chain residue of the only Trp residue in AE105 is indispensable for the high-binding affinity toward uPAR as reported previously (2, 13) . The present Trp!Glu replacement of this hotspot residue is accordingly accompanied by a >2,300-fold reduction in uPAR binding as assessed by various biochemical assays (Fig. 2) , and as a consequence, the 64 Cu-labeled peptide showed only minimal uptake in U87 tumor (Figs. 4 and 5 ). This finding argued strongly for the specificity of the in vivo labeling of the U87MG tumors by 64 Cu-DOTA-AE105. Further substantiating this specificity was the observation that a bolus injection of a nonradioactive AE105 peptide successfully blocked the uptake of 64 Cu-DOTA-AE105 in U87MG tumor (Fig. 4) . A low residual tumor uptake of 64 Cu-DOTA-AE105 was nevertheless observed despite preloading the mice with the unlabeled peptide. A moderate degree of ''passive targeting'' to the U87MG tumor of 64 Cu-DOTA-AE105 due to leaky tumor vasculature could perhaps account for this residual activity, the level of which resembled the one obtained with the non-uPAR-binding 64 Cu-DOTA-AE105 mut (compare Fig. 5B and C) . It is worth mentioning that although the dissociation rate constant for the DOTA-AE105-uPAR complex is relatively fast (t 1/2 < 2 minutes) as determined by surface plasmon resonance under very high flow conditions and that the pharmacologic half-life of this small-sized peptide tracer is expectedly low in the circulation, we nonetheless observed a prolonged retention of 64 Cu-DOTA-AE105 in microenvironments having relatively high uPAR expression such as in U87MG tumors. This phenomenon presumably arises as a combined effect of the relatively slow off-rate of the peptideuPAR complex and a significant rebinding due to an inefficient tumor leaching of any dissociated tracer. Receptor-mediated internalization of the tracer and intracellular trapping of the radiometal could also facilitate the retention of the tracer within the tumor sites.
Although we have rigorously proven the specificity in targeting uPAR with the radioligand 64 Cu-DOTA-AE105, it is not yet known whether this radiotracer actually would allow a quantitative measurement of receptor expression in vivo.
Systematic approaches using multiple tumor models with differentiated uPA/uPAR expression level will have to be tested and the tumor uptake and tumor contrast be correlated with the receptor level quantified by Western blot. Interference from shed uPAR circulating in plasma from cancer patients is not considered a major problem for the present imaging studies due to the low abundance of soluble uPAR (30-200 pmol/L; ref. 42) . The liver uptake of 64 Cu-DOTA-AE105 is relatively high in the present protocol and may limit its applicability to measure lesions in the liver and intestines. Further modification is thus needed to improve the pharmacokinetics of this radiopharmaceutical and one possibility is to use a soluble pseudosymmetrical dimer of AE105 displaying a higher affinity for uPAR and increased solubility (13) . Future studies may also focus on developing various imaging or therapeutic probes based on peptide sequences identified from bacteriophage display and combinatorial peptide/peptidomimetic library with higher receptor affinities.
It has been shown that uPA-uPAR binding is species specific with little cross-reactivity between human and murine proteins Regions of interest are shown as the %ID/g F SD (n = 3). (43) . A similar selectivity is applied to the use of the peptide antagonists used in the present study as revealed by binding studies using surface plasmon resonance (that is, human uPAR binds the immobilized synthetic peptide with a nanomolar affinity, whereas a specific binding to purified mouse uPAR remained undetectable even at 1 Amol/L; ref. 13) . In the present PET imaging studies of xenotransplanted human tumors in mice, it is therefore most unlikely that 64 Cu-DOTA-AE105 will bind mouse uPAR expressed by the tumor-associated murine stroma and vasculature cells. At least in some human malignancies the tumor-associated stroma accounts for a significant fraction of the tumor associated uPAR expression, which will not be detected in the present xenotransplanted model. As this consideration is irrelevant in human cancer, the specific PET imaging by the peptide antagonist may also be applicable to cancers where uPAR are predominantly expressed by the tumor-associated stroma rather than the cancer cells themselves (e.g., colorectal cancer; ref. 1).
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